Institutional Investment Pitches
Explore thousands of hedge fund pitches, high-conviction equity research memos, and portfolio manager commentary extracted from quarterly letters.
Explore thousands of hedge fund pitches, high-conviction equity research memos, and portfolio manager commentary extracted from quarterly letters.
We sold Boston Scientific on concerns around continued pressure in its two growth engines: the Watchman device and Farapulse. Despite good data...
— Mr. Fitzpatrick
Full equity research memos, financial breakdowns, and hedge fund thesis write-ups are reserved for BSD Research ($50/mo) and Pro subscribers.
Already a Research or Pro subscriber? Sign In
Other investors who've written on Boston Scientific
Boston Scientific ($BSX) represents 5.7% of the fund's portfolio. The company designs,...
A highly innovative pipeline in cardiology and other medtech spaces continues to fuel double-digit revenue growth and operating leverage. Recent stock declines...
More institutional theses from Aristotle Core Equity Fund
Chart Industries posted positive performance as preliminary 2025 outlooks indicated robust 39% earnings growth despite a Q3 quarterly miss. Management reiterated solid...
The fund established a long position in CrowdStrike to capture secular growth in enterprise cloud migration and security spending. The company's unified...
Aristotle initiated a position in GE Aerospace, citing its dominant position in high-barrier commercial engine manufacturing and long OEM order backlogs. Following significant corporate...